With the increasing use of Generative AI in the pharmaceutical industry, and the evolving regulations and guidance from various regulatory authorities, IMPALA aims to outline some key principles and guidelines helping the industry to adopt GenAI while assessing the risks and establishing the right controls to ensure safe use.

Goal

Share the best practices, key considerations and validation approach when implementing GenAI in the biopharma industry.

Expected Outcomes

White paper outlining key principles, best practices, and considerations when utilising GenAI in the biopharmaceutical industry.

Lead(s)

Resources